GlassScriptPhysician profile
Marion S Johnson
NPI 1952523086
$4,079.40
in general payments reported to CMS, 2019-2025
23 companies · $734 in 2025
The $734 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $580 · 2021: $406 · 2022: $837 · 2023: $538 · 2024: $615 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $823.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $467.92 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $398.01 | 2019-2024 | Nucala |
| Astrazeneca Pharmaceuticals LP | $347.22 | 2019-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $266.38 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $260.82 | 2020-2024 | Takhzyro |
| Pharming Healthcare, INC. | $179.10 | 2020-2023 | Ruconest |
| Novartis Pharmaceuticals Corporation | $155.33 | 2019-2025 | |
| Pfizer INC. | $125.23 | 2019-2023 | |
| Kaleo, INC. | $124.39 | 2020-2022 | |
| Grifols USA, LLC | $113.71 | 2022-2025 | Xembify |
| Csl Behring | $109.84 | 2021-2023 | Haegarda |
| Ars Pharmaceuticals Operations, INC. | $105.78 | 2025 | Neffy |
| Amgen INC. | $96.57 | 2022-2023 | Tezspire |
| Covis Pharma Gmbh | $94.35 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $77.85 | 2021 | |
| Cycle Pharmaceuticals INC | $62.87 | 2025 | Sajazir |
| Genentech USA, INC. | $61.61 | 2020-2025 | Xolair |
| Ionis Pharmaceuticals, INC. | $59.73 | 2025 | Dawnzera |
| Biocryst Pharmaceuticals, INC. | $55.85 | 2020 | |
| Octapharma USA, INC. | $49.72 | 2020-2022 | |
| Optinose US, INC. | $24.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.